Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells

International Journal of Cancer

Volumn 130, Issue 11, 2012, Pages 2607-2617

  Baumgaertner, Petra ^a   Jandus, Camilla ^a   Rivals, Jean Paul ^a   Derré, Laurent ^a   Lövgren, Tanja ^a   Baitsch, Lukas ^a   Guillaume, Philippe ^a   Luescher, Immanuel F ^a   Berthod, Gregoire ^a   Matter, Maurice ^a   Rufer, Nathalie ^a   Michielin, Olivier ^a   Speiser, Daniel E ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

CD8 T cell effector function; CpG oligodeoxynucleotides; Melan A MART 1 peptide; melanoma; vaccination

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MELAN A; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STAT1 PROTEIN; STAT5 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER IMMUNIZATION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE FREE SURVIVAL; ENZYME PHOSPHORYLATION; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOCYTE RECIRCULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

ADULT; AGED; ANTIGENS, CD3; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; IMMUNOCOMPETENCE; MALE; MART-1 ANTIGEN; MIDDLE AGED; PHOSPHORYLATION; STAT1 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; VACCINATION;

EID: 84859160195     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26297     Document Type: Article

References (50)

1. Speiser DE, Kyburz D, Stübi U, Hengartner H, Zinkernagel RM,. Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities: low T cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide coated target cells but not for in vivo protection. J Immunol 1992; 149: 972-80.
2. Alexander-Miller MA, Leggatt GR, Berzofsky JA,. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA 1996; 93: 4102-7.
3. Messaoudi I, Guevara Patino JA, Dyall R, LeMaoult J, Nikolich-Zugich J,. Direct link between MHC polymorphism, T cell avidity, and diversity in immune defense. Science 2002; 298: 1797-800.
4. Obar JJ, Khanna KM, Lefrancois L,. Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection. Immunity 2008; 28: 859-69.
5. Moon JJ, Chu HH, Pepper M, McSorley SJ, Jameson SC, Kedl RM, Jenkins MK,. Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity 2007; 27: 203-13.
6. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, Bornstein E, Asher TE, Samri A, Schnuriger A, Theodorou I, Costagliola D, Rouzioux C, et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 2007; 204: 2473-85.
7. Lichterfeld M, Yu XG, Mui SK, Williams KL, Trocha A, Brockman MA, Allgaier RL, Waring MT, Koibuchi T, Johnston MN, Cohen D, Allen TM, et al. Selective depletion of high-avidity human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells after early HIV-1 infection. J Virol 2007; 81: 4199-214.
8. Appay V, Douek DC, Price DA,. CD8+ T cell efficacy in vaccination and disease. Nat Med 2008; 14: 623-8.
9. Seder RA, Darrah PA, Roederer M,. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8: 247-58.
10. Kochenderfer JN, Gress RE,. A comparison and critical analysis of preclinical anticancer vaccination strategies. Exp Biol Med (Maywood) 2007; 232: 1130-41.
11. Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D, Liu C, Lesokhin AM, Sahawneh D, Zhong H, Panageas KS, Perales MA, Altan-Bonnet G, Wolchok JD, Houghton AN,. Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med 2009; 206: 849-66.
12. Fearon DT, Manders P, Wagner SD,. Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. Science 2001; 293: 248-50.
13. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia R, von Andrian UH, Ahmed R,. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003; 4: 225-34.
14. Klebanoff CA, Gattinoni L, Restifo NP,. CD8 T-cell memory in tumor immunology and immunotherapy. Immunol Rev 2006; 211: 214-24.
15. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, Murali-Krishna K, Mahar PL, Edupuganti S, Lalor S, Germon S, Del Rio C, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008; 28: 710-22.
16. Riddell SR, Greenberg PD,. Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol 1995; 13: 545-86.
17. Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P,. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005; 115: 739-46.
18. Derre L, Rivals JP, Jandus C, Pastor S, Rimoldi D, Romero P, Michielin O, Olive D, Speiser DE,. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest 2010; 120: 157-67.
19. Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, O'Neill D, Pavlick A, Escalon JB, Cruz CM, Angiulli A, Angiulli F, Mears G, et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 2007; 104: 8947-52.
20. Tyagi P, Mirakhur B,. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 2009; 10: 371-4.
21. Roederer M, Nozzi JL, Nason MC,. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 2011; 79: 167-74.
22. Appay V, Jandus C, Voelter V, Reynard S, Coupland SE, Rimoldi D, Liénard D, Guillaume P, Krieg A, Cerottini JC, Romero P, Leyvraz S, et al. New generation vaccine in humans induces effective melanoma specific CD8+ T cells in circulation but not in the tumor site. J Immunol 2006; 177: 1670-8.
23. Park JH, Adoro S, Lucas PJ, Sarafova SD, Alag AS, Doan LL, Erman B, Liu X, Ellmeier W, Bosselut R, Feigenbaum L, Singer A,. "Coreceptor tuning": cytokine signals transcriptionally tailor CD8 coreceptor expression to the self-specificity of the TCR. Nat Immunol 2007; 8: 1049-59.
24. Linton PJ, Dorshkind K,. Age-related changes in lymphocyte development and function. Nat Immunol 2004; 5: 133-9.
25. Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP,. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 2007; 4: e176.
26. Mortarini R, Vegetti C, Molla A, Arienti F, Ravagnani F, Maurichi A, Patuzzo R, Santinami M, Anichini A,. Impaired STAT phosphorylation in T cells from melanoma patients in response to IL-2: association with clinical stage. Clin Cancer Res 2009; 15: 4085-94.
27. Adamson AS, Collins K, Laurence A, O'Shea JJ,. The current status of lymphocyte signaling: new roles for old players. Curr Opin Immunol 2009; 21: 161-6.
28. Speiser DE, Romero P,. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Semin Immunol 2010; 22: 144-54.
29. Dworacki G, Meidenbauer N, Kuss I, Hoffmann TK, Gooding W, Lotze M, Whiteside TL,. Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res 2001; 7: 947s-57s.
30. Franco JL, Ghosh P, Wiltrout RH, Carter CR, Zea AH, Momozaki N, Ochoa AC, Longo DL, Sayers TJ, Komschlies KL,. Partial degradation of T-cell signal transduction molecules by contaminating granulocytes during protein extraction of splenic T cells from tumor-bearing mice. Cancer Res 1995; 55: 3840-6.
31. Adachi K, Davis MM,. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells. Proc Natl Acad Sci USA 2011; 108: 1549-54.
32. Perez OD, Mitchell D, Jager GC, South S, Murriel C, McBride J, Herzenberg LA, Kinoshita S, Nolan GP,. Leukocyte functional antigen 1 lowers T cell activation thresholds and signaling through cytohesin-1 and Jun-activating binding protein 1. Nat Immunol 2003; 4: 1083-92.
33. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci 2008; 105: 20410-5.
34. Precopio ML, Betts MR, Parrino J, Price DA, Gostick E, Ambrozak DR, Asher TE, Douek DC, Harari A, Pantaleo G, Bailer R, Graham BS, et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 2007; 204: 1405-16.
35. Speiser DE, Baumgaertner P, Barbey C, Rubio-Godoy V, Moulin A, Corthesy P, Devevre E, Dietrich PY, Rimoldi D, Lienard D, Cerottini JC, Romero P, et al. A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. J Immunol 2006; 177: 1338-48.
36. Derre L, Bruyninx M, Baumgaertner P, Devevre E, Corthesy P, Touvrey C, Mahnke YD, Pircher H, Voelter V, Romero P, Speiser DE, Rufer N,. In vivo persistence of codominant human CD8+ T cell clonotypes is not limited by replicative senescence or functional alteration. J Immunol 2007; 179: 2368-79.
37. Azuma M, Phillips JH, Lanier LL,. CD28-T lymphocytes. Antigenic and functional properties. J Immunol 1993; 150: 1147-59.
38. Posnett DN, Engelhorn ME, Lin Y, Merghoub T, Duan F, Wolchok JD, Houghton AN,. Development of effective vaccines for old mice in a tumor model. Vaccine 2009; 27: 1093-100.
39. Bodey B, Bodey B, Jr, Siegel SE, Kaiser HE,. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res 2000; 20: 2665-76.
40. Allavena P, Sica A, Garlanda C, Mantovani A,. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 2008; 222: 155-61.
41. Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, Zanon A, Rossi CR, Nitti D, Bronte V, Zanovello P,. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol 2009; 182: 6562-8.
42. Gabrilovich DI, Nagaraj S,. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-74.
43. Speiser DE, Baumgaertner P, Voelter V, Devevre E, Barbey C, Rufer N, Romero P,. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci USA 2008; 105: 3849-54.
44. Cole DK, Edwards ES, Wynn KK, Clement M, Miles JJ, Ladell K, Ekeruche J, Gostick E, Adams KJ, Skowera A, Peakman M, Wooldridge L, et al. Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition. J Immunol 2010; 185: 2600-10.
45. Wieckowski S, Baumgaertner P, Corthesy P, Voelter V, Romero P, Speiser DE, Rufer N,. Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients. J Immunol 2009; 183: 5397-406.
46. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003; 198: 569-80.
47. Nichols LA, Chen Y, Colella TA, Bennett CL, Clausen BE, Engelhard VH,. Deletional self-tolerance to a melanocyte/melanoma antigen derived from tyrosinase is mediated by a radio-resistant cell in peripheral and mesenteric lymph nodes. J Immunol 2007; 179: 993-1003.
48. Zehn D, Bevan MJ,. T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity 2006; 25: 261-70.
49. Mueller DL,. Mechanisms maintaining peripheral tolerance. Nat Immunol 2010; 11: 21-7.
50. Baitsch L, Baumgaertner P, Devevre E, Raghav SK, Legat A, Barba L, Wieckowski S, Bouzourene H, Deplancke B, Romero P, Rufer N, Speiser DE,. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. J Clin Invest 2011; 121: 2350-60.